Pediatric Liver Transplantation: Then and Now by Tran, LT et al.
~ote In: lrth?topicK~iver Transplantation_ (Gips CH and Krom RAF, Eds.). Martlnus N1Jhoff Publishers, The Hague, The Netherlands,1 1S84. 
e{f[( VkV 
n ~KIK- (Symposium on liver transplantation at Groningen, 
j//)/)(:\;;1" '-'<A I . ;/" fj:rgC~C~ 
~/ The Netherlands, May 19, 1983) 
PEDIATRIC LIVER TRANSPLANTATION 
Shunzaburo Iwatsuki, M.D. 
Thomas E. Starzl, M.D., Ph.D. 
Byers W. Shaw, Jr., M.D. 
J. Carlton Gartner, M.D. 
Basil J. Zitelli, M.D. 
J. Jeffrey Malatack, M.D. 
From the Department of Surgery, University Health Center of Pittsburgh, Uni-
versity of Pittsburgh, Pittsburgh, Pennsylvania, and Children's Hospital of 
Pittsburgh, Pittsburgh, Pennsylvania. 
Reprint requests should be sent to: Shunzaburo Iwatsliki, M.D., Department of 
Surgery, University Health Center of Pittsburgh, 1084 Scaife Hall, Pittsburgh, 
PA 15261. 
Supported by research grants from the Veterans Administration, National In-
stitutes of Health Bethesda, Grant No AM29961. 
- 2 -
The value of cadaveric organ transplantation in infants and children has 
been often questioned because of the unsatisfactory survival and high morbid-
ity associated with the conventional immunosuppressive regimen which includes 
azathioprine and prednisone, with or without antilymphocyte globulin. Even 
after so-called "successful" transplantation the quality of life has been 
degraded too often by the side effects of high-dose steroid therapy, such as 
Cushingoid changes, growth retardation and osteoporosis. 
Despite the continued efforts over the last twenty years to improve the 
survival and the quality of life after organ transplantation, real progress 
had to await the discovery (1, 2) and clinical use (3-6) of cyclosporine, a 
potent immunosuppressive agent derived from the fungi Cyclidrocarpon lucidum 
and Trichoderm polysporum. 
We are reporting here the progress of liver transplantation in infants 
and children comparing the results obtained by using a regimen of cyclosporine 
and low dose steroids to those obtained in the past with the use of conven-
tional immunosuppressive therapy. 
CASE MATERIALS AND METHODS 
Since the first human orthotopic liver transplantation on March 1, 1963, 
296 patients with various diseases have received liver homografts as of April 
30 1983 at the University of Colorado and the University of Pittsburgh. Of 
those 296 recipients, 170 were treated before March, 1980 with conventional 
double or triple drug therapy, including azathioprine (or cyclophosphamide), 
prednisone and antilymphocyte globulin. The remaining 126 were transplanted 
since March, 1980, and were treated with cyclosporine and low dose predni-
sone. Among the 170 patients given conventional immunosuppression therapy, 86 
were pediatric recipients under age 18. Of 100 consecutive liver graft recip-
ients under cyclosporine-low dose steroid therapy since March, 1980 there were 
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40 pediatric recipients under age 18. The experiences obtained from the total 
of these 126 pediatric liver recipients form the basis of this report. 
Age Distribution 
The age distribution of the 86 pediatric recipients under conventional 
therapy and the 40 patients under cyclosporine therapy is shown in Figure 
1. Seventy-four recipients were younger than 6 years old, 29 were between 6 
and 12 years old and 23 were older than 12 years old. 
Indications for Liver Transplantation 
The main indications for liver transplantation in 126 pediatric orthoto-
pic liver recipients are shown in Table 1. Biliary atresia or hypoplasia 
accounted for over one half of the total pediatric liver transplantations and 
was the most cormnon diagnosis. The second most common indication was an 
inborn error of metabolism, such as alph-1-antitrypsin deficiency disease, 
Wilson's disease, tyrosinemia, glycogen storage disease, and sea blue histio-
cyte syndrome. 
Primary liver malignancy which could not be treated by partial hepatic 
resection once was thought to be an ideal indication for orthotopic liver 
transplantation. However, previous experiences (7-12) indicated that malig-
nant tumor recurred in most cases if the malignancy was diagnosed before 
transplantation and was the major indication for transplantation. On the 
other hand, if the malignancy was an incidental finding, whether known in 
advance or found only after examination of the removed specimen, or the ma-
lignancy is confined wholly to the liver, cure could be achieved by an ortho-
topic hepatic transplantation. Ten pediatric patients with primary hepatic 
malignancy (9 hepatomas and 1 hepatoblastoma) have received liver grafts. In 
three of them a malignant tumor was the main indication for transplantation 
but it was an incidental finding in the remaining seven. Of the seven pa-
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tients with incidental malignancies, three were among 71 recipients with 
biliary atresia, two were patients with tyrosinemia, one a patient with alpha-
1-antitrypsin deficiency disease and one patient with sea-blue histiocyte 
syndrome (Table 1, Foot-note). 
Immunosuppressive Therapy 
The conventional method of immunosuppression, involving the combination 
of azathioprine and prednisone with or without antilymphocyte globulin (7-9, 
13-15) or the substitution of cyclophosphamide (16) for azathioprine, had been 
reported extensively and in detail elsewhere. 
Since March, 1980, combination immunosuppressive therapy with cyclo-
sporine and low-dose prednisone has been used in all liver transplantations 
(12, 17, 18). Cyclosporine is administered before liver grafting in an oral 
dose of 17.5 mg/kg or an intravenous dose of 5 to 6 mg/kg. Soon after the 
operation cyclosporine is given intravenously as a dose of 5 to 6 mg/kg/day in 
2 to 3 divided doses. When the patient can resume oral intake, 17.5 mg/kg/day 
of cyclosporine in two divided doses is given and intravenous doses are grad-
ually withdrawn, depending upon the renal function, graft function and blood 
level of cyclosporine. Maintenance doses of cyclosporine are adjusted mainly 
on the nephrotoxicity of the drug. Usually the dose is in the 12 mg/kg/day 
range at one month and 10 mg/kg/day at six months in pediatric recipients. 
Infants and younger children seem to tolerate the drug better than older 
children and adults. 
Steroids are a necessary addition to cyclosporine to achieve adequate 
immunosuppression, but the doses used are much less than those required in 
combination with azathioprine. Soon after revascularization of the liver, 
graft recipients receive 250 or 500 mg of intravenous methylprednisolone 
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succinate, with those recipients weighing more than 20-30 Kg usually receiving 
the higher dose. 
Postoperatively, the daily dose of methylprednisolone or prednisone is 
tapered by 20 mg daily, from 100 mg daily on the first day down to a mainten-
ance dose of 10 mg on the sixth day. Further reduction of the steroids dose 
depends upon graft function. Usually the children are discharged with a 
maintenance dose of prednisone of 5 mg/day one to two months after transplan-
tation. Initial and maintenance doses of steroids are reduced in infants and 
smaller children, and are increased in larger children. 
If rejection occurs despite the above outlined immunosuppressive therapy, 
boluses of intravenous steroid therapy and/or a recycle of the original 5-day 
burst of prednisone therapy are given immediately. Although cyclosporine does 
not permit much dose manEUverability, it is often possible in infants and 
children to increase the dose with little risk of nephrotoxicity. 
If severe nephrotoxicity was suspected, cyclosporine doses were reduced 
or the drug was substituted by azathioprine, often with rapid reversal of 
acute renal failure. The dose of cyclosporine was also reduced in the face of 
severe infectious complications. 
Donor Operation 
The liver, heart and kidneys can be procured from a single donor without 
compromising the anatomy and function of any of the organs. The technique of 
multiple organ procurement and the early functions of each organ graft have 
been reported (19, 20). The incidence of first week dialysis in patients 
receiving renal allografts procured in combination with livers and hearts or 
both is less than 15%. In addition satisfactory livers and hearts usually can 
be obtained unless there has been faulty donor selection. 
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The techniques of donor hepatectomy in children are essentially the same 
as those in adults (7, 19). However, it is advisable in pediatric liver 
donors to obtain the celiac axis in continuity with the upper abdominal and 
thoracic aorta and use the latter for anastomosis with the recipients lower 
abdominal aorta if it is necessary. If the hepatic graft receives an addi-
tional blood supply from the superior mesenteric artery, both the celiac axis 
and the superior mesenteric artery can be obtained in continuity with the 
upper abdominal and thoracic aorta, particularly in an infant or small child 
donor (20). 
Recipient Operation 
The techni ques of orthotopic liver transplantation had been established 
more than 15 years ago (7) and several minor modifications have been reported 
(8, 21-24). 
In children a bilateral subcostal incision or upper abdominal transverse 
incision using a previous incision almost always gives an adequate exposure. 
Recipient hepatectomy in children is usually easier than that in adults. 
The most important area wherein pediatric hepatic transplants require 
particular attention to detail is in the performance of the vascular anasto-
mosis. We employ a continuous suture using monofilament polypropylene for all 
vascular anastomoses. To avoid the purse stringing which can easily occur 
wi th this technique, care is taken to prevent undue traction upon the su-
tures. Nevertheless, a "growth factor" technique, described elsewhere in 
detail (24) is left in all vascular suture lines, particularly the arterial 
and portal vein anastomoses. Every effort should be directed toward elimina-
ting strictures in these suture lines so that turbulent flow and pressure 
gradients are minimized across the anastomoses. 
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The order of anastomoses can vary following completion of the suprahepa-
tic vena cava connection. Most commonly the infrahepatic vena cava anastomo-
sis is made next followed by the portal vein, followed by release of the flow 
through the latter, the lower and upper vena cava channels. The arterial 
anastomosis is then completed while the liver is perfused by portal vein flow. 
In the face of cardiodynamic instability caused by vena caval interrup-
tion, or if portal vein clamping appears to be causing undue damage to the 
intestine the portal vein anastomosis can be done following the upper vena 
cava and flow through the liver restored with the infrahepatic vena caval ends 
clamped. The latter can then be reconnected as the third anastomosis. 
In addition, one may wish to complete the arterial anastomosis before the 
portal vein if portal vein flow appears to be inadequate, as may be the case, 
for example, in some biliary atresia patients with small, sclerotic native 
portal veins. Finally, all four vascular anastomoses often can be completed 
in less than 60 - 70 minutes and arterial and portal vein flow restored to the 
hepatic graft simultaneously. 
Bile duct reconstruction methods in pediatric cases are similar to those 
in adults (7, 25, 26). End-to-end choledochocholedochostomy with aT-tube 
stent is used whenever recipient anatomy and size permit. In-dwelling inter-
nal stents are often necessary for very small bile ducts. In cases of biliary 
atresia and other bile duct disorders a satisfactory native bile duct is not 
available and end-to-side anastomosis of graft common duct to a Roux-en-Y loop 
of jejunum is employed. These also are stented internally. 
Cholecystojejunostomy or other methods which depend entirely upon drain-
age via the cystic duct are now avoided entirely because of the high incidence 
of obstruction of the cystic duct by sludge in transplanted livers which 
undergo even minor rejection episodes (25, 27). Operati ve cholangiograms 
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through either a T-tube or the graft cystic duct stump are performed to docu-
ment duct anatomy, patency and competency. 
RESULTS 
Causes of Death 
Fifty-three of the 86 pediatric liver recipients between 1963 and 1980 
(precyclosporine era) and 14 of the 40 between 1980 and 1982 (cyclosporine 
era) died within a year after transplantation. Detailed clinical-pathologic 
analyses of almost all of these deaths has been reported, using OT code num-
bers (7-9, 12, 28). Although the causes of deaths in these patients were usu-
ally multiple, they were categorized to the best of our knowledge as shown in 
Table 2. 
During the precyclosporine era bacterial, fungal and viral infections 
were the main cause of deaths within a year after transplantation (20 of 53 
deaths) • There were 9 deaths from abdominal sepsis, 5 deaths from viral 
infection (adenovirus, chickenpox and herpes), 4 deaths from systemic bacter-
ial and fungal sepsis and 2 deaths from pulmonary infection. Although infec-
tious complications continue to be a major threat to life after transplanta-
tion none of the 14 deaths under cyclosporine therapy was categorized death 
from infection. 
Significant numbers of deaths were caused by surgical technical complica-
tions of arterial, venous or biliary anastomoses. In the precyclosporine era 
there were 15 deaths in this category. Eight of the 15 were failures in 
biliary duct reconstruction, 4 in hepatic artery anastomosis, 2 in portal 
venous anastomosis and 1 in suprahepatic inferior vena caval anastomosis. In 
the cyclosporine era surgical technical complications were the direct cause of 
death in 7 of the 14 children. There were 3 failures in hepatic artery anas-
tomoses, and one each in both the hepatic artery and portal vein anastomosis, 
- 9 -
portal venous anastomosis, suprahepatic vena caval anastomosis, and biliary 
duct reconstruction. 
Acute and chronic graft rejection were the third main cause of death in 
the precyclosporine era and the second in the cyclosporine era. Despite the 
better immunosuppression therapy and the improved survival with cyclosporine 
approximately 10 per cent of the recipients died from graft rejection both in 
the precyclosporine era and in the cyclosporine era. 
Survival 
One Year Survival: 
Actual survival of 86 pediatric liver recipients in the precyclosporine 
era and actuarial survival of 40 pediatric recipients in the cyclosporine era 
are shown in Figure 2. After the introduction of cyclosporine the one year 
survival after liver transplantation improved from 40% to 62%. 
Age and Survival: 
Because the majority of deaths within the first year occurred within 
three months after liver transplantation the three month survival of each age 
group is compared in Figure 1. In the precyclosporine era 28 of 53 (53%) 
infants and preschool children (less than 6 years old), 8 of 16 (50%) school 
age children (between 6 and 12 years old), and 13 of 17 (76%) adolescents 
lived more than 3 months. In the cyclosporine era 16 of 21 (76%) infants and 
preschool children, 8 of 12 (67%) school children and 6 of 7 (86%) adolescents 
Ii ved more than three months. Both in the precyclosporine era and in the 
cyclosporine era 3 month survival of infants and preschool 0hildren was sta-
tistically not different from those of school children. Three month survival 
of the adolescents was slightly better than those of younger children in both 
eras. 
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It is worthwhile to note that 5 of 7 (71%) infants (less than a year old) 
lived more than three months. The technical difficulties in infant surgery 
have been fairly well overcome in liver transplantation as well. The age of 
children should not be a consideration in accepting them as candidates for 
liver transplantation. Our youngest recipients have been 3 and 6 months. 
Liver Disease and Survival: 
The influence of original liver disease upon survival was analyzed in the 
two most common indications (biliary atresia and inborn metabolic errors) of 
pediatric liver transplantation, and shown in Figures 3 and 4. Both in the 
precyclosporine era and the cyclosporine era survival of children with inborn 
metabolic errors was significantly better than those of children with biliary 
atresia. The survival of children with biliary atresia was lower than overall 
survival in the precyclosporine era, but it was similar to the overall survi-
val in the cyclosporine era. This improvement in survival of children with 
biliary atresia my well reflect the better surgical techniques, management 
and immunosuppression with cyclosporine. 
Five Year Survival: 
Seventy-five pediatric patients received liver transplantation more than 
5 years ago (precyclosporine era). Sixteen of the 75 (21%) lived more than 5 
years, and 15 are still alive between 5 and 14 years after transplantation as 
of April, 1983. All but two have normal liver function and attend school or 
work full time. Two patients with abnormal liver function lost their jobs 
recently. 
Long term survival data in the cyclosporine era is not available yet, but 
13 children are alive and in good health between one and three years after 
transplantation. 
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DISCUSSION 
Since the introduction of cyclosporine, the results of organ transplanta-
tion such as kidney (5, 6, 29), liver (12, 17, 18), and heart (30), have 
improved significantly. 
In combination with a low dose steroid, cyclosporine provides more effec-
tive and safer immunosuppression than conventional double or triple drug 
immunosuppression therapy (azathioprine and prednisone with or without anti-
lymphocyte globulin). In pediatric liver transplantation the one year survi-
val improved from 40% to 62% with cyclosporine and low dose steroid therapy. 
Infectious complications, which had been the most frequent direct cause of 
death after liver transplantation with conventional immunosuppression therapy, 
became less frequent and more treatable under this new immunosuppression 
therapy. Children can grow at a normal or better rate after transplantation 
and complications of high dose steroids such as Cushingoid feature and osteo-
pathy have been virtually eliminated. 
The opinion that infants and small children may not be good candidates 
for liver transplantation because of age and size has been proved incorrect. 
Survivals of infants and smaller children have been as good as larger chil-
dren, and survivals of pediatric recipients have been better than those of 
adults both in the precyclosporine and the cyclosporine era. 
The original liver disease has had some influence upon the outcome of 
transplantation. Children with liver-based inborn metabolic errors have done 
better than those with biliary atresia or hypoplasia. This is partly due to 
the fact that previous major surgeries such as Kasai operation (for biliary 
atresia) make the transplantation operation more difficult; anatomic anomalies 
have been an additional factor. However, in the cyclosporine era the results 
of liver transplantation for biliary atresia has raised to the level of over-
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all survivals of pediatric cases, but it is till inferior to that after treat-
ment of inborn metabolic errors. 
Survival and quality of life after liver transplantation have improved 
significantly since the introduction of cyclosporine, and it has become a 
reliable method of therapy for otherwise untreatable liver diseases. As the 
experience in pediatric liver transplantation expands and deepens, further 
improvement of outcomes and better understanding of various liver disease can 
be expected. 
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FIGURES 
Figure 1. Age distribution of 126 pediatric liver recipients. A shaded 
square represents a child who survived more than 3 months, and a 
black square represents a child who died within 3 months. 
Figure 2. A comparison of survival after liver transplantation between 86 
pediatric liver recipients under conventional immunosuppression 
therapy (azthioprine, prednisone and ALG) and 40 pediatric 
recipients under cyclosporine-prednisone therapy. 
Figure 3. Influence of original liver disease upon one year survival under 
conventional immunosuppression therapy. 
Figure 4. Influence of original liver disease upon one year survival under 
cyclosporine-steroid therapy. 
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